Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance
about
Inadequate use and regulation of interventions against publication bias decreases their effectiveness: a systematic reviewThe importance of clinical trial data sharing: toward more open scienceUsing real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.Accumulating research: a systematic account of how cumulative meta-analyses would have provided knowledge, improved health, reduced harm and saved resources.Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.A model for dissemination and independent analysis of industry data.Trends in Prescription Drug Use Among Adults in the United States From 1999-2012.Persistence of cardiovascular risk after rofecoxib discontinuation.Neoliberalism, conflict of interest, and the governance of health research in CanadaCausal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx.FDA Policy and Cardiovascular Medicine.Relevance of pharmacoepidemiology to NepalDelays in psychiatric drug development in Japan.Managing cardiovascular risk in patients with chronic inflammatory diseases.Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions.Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure.Promoting transparency in pharmaceutical industry-sponsored research.Cardiovascular Safety in Drug Development: A Role for Endothelial Function Tests.Electronic healthcare databases for active drug safety surveillance: is there enough leverage?Catching Chances: The Movement to Be on the Ground and Research Ready before an OutbreakLink between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter CohortStudying additive interaction in a healthcare database: Case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction
P2860
Q26995526-7DC35573-0BC4-4E77-92DE-C8598060BF93Q28730765-EABDE728-6B1F-4D44-9D9E-F92F974655A8Q30875888-80F49B11-03EF-4F8B-AB2F-5E956BBA2813Q33583631-0E4AEAE8-9298-4CFC-B5F9-B1665224A2B9Q33961015-2804A3CE-C309-46B3-B193-B95A40992135Q33989306-A022F45B-661E-4C97-B815-4D27494E2AD9Q34046947-BF4B93DD-E6CC-4EB8-9A6E-2DC612646D40Q34500310-5E5A347D-61D2-45FC-B829-834F3421CF45Q34510157-EE3C4BC2-0888-4BAC-8D43-7179CE854CEAQ35049842-D3EF26CB-4796-49DA-84F7-DA7CC538BDA6Q36070087-5B91372C-E644-45B9-983B-BE901D043C04Q36100416-5D6929BC-92E9-46F0-B0A8-96C03F6416D7Q37224284-24A7A634-0B1B-4359-BBAE-C1D8C3C13D1DQ37948093-1B520212-0D78-45D0-ACCA-D597CC408A79Q37975943-03E9E71B-41DB-461D-AA84-C038B8E4E53DQ38941017-EB4BFA6D-8C09-4198-986F-2BC024FE8E98Q38974360-14A4CB82-AAC6-4CFD-B3DA-3E56D23341D3Q41889038-D64D6C02-B65D-40FF-80C7-45C85292984BQ48242991-7A7EC487-F604-4A33-8DA2-83D000E92F58Q53091529-B1EA0536-7DA6-4197-8FB1-9A46F8089B38Q53139178-DE19EC6D-BD2F-4DFC-8C8E-167D7C4B17CFQ53668416-479ACD16-037E-4AF3-B89A-043F71AD897CQ56535643-8B6440A5-6272-40B8-B3FD-1B2088F6A598Q57658287-488D9A83-936B-4146-BB64-014A4E4C57A3Q58791320-653F9FD5-9E65-47F1-94D1-A342CC40D470
P2860
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pooled analysis of rofecoxib p ...... maceutical safety surveillance
@ast
Pooled analysis of rofecoxib p ...... maceutical safety surveillance
@en
Pooled analysis of rofecoxib p ...... aceutical safety surveillance.
@nl
type
label
Pooled analysis of rofecoxib p ...... maceutical safety surveillance
@ast
Pooled analysis of rofecoxib p ...... maceutical safety surveillance
@en
Pooled analysis of rofecoxib p ...... aceutical safety surveillance.
@nl
prefLabel
Pooled analysis of rofecoxib p ...... maceutical safety surveillance
@ast
Pooled analysis of rofecoxib p ...... maceutical safety surveillance
@en
Pooled analysis of rofecoxib p ...... aceutical safety surveillance.
@nl
P2093
P2860
P1476
Pooled analysis of rofecoxib p ...... maceutical safety surveillance
@en
P2093
David Madigan
David S Egilman
Kevin P Hill
Yongfei Wang
P2860
P304
P356
10.1001/ARCHINTERNMED.2009.394
P407
P577
2009-11-01T00:00:00Z